Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Radiology
•
Inflammatory arthritis
•
Nuclear Medicine
When would you consider utilizing bone scintigraphy in the assessment of inflammatory arthritis?
Answer from: at Community Practice
When it's a case of negative RA disease or when considering a neoplastic, gammopathy with myeloma...
Sign in or Register to read more
Answer from: at Community Practice
I would also consider using triple phase bone scan to assess the blood pool phase which may help determine sites of active inflammation. This may also help guide sites for intervention/injection.
Sign in or Register to read more
14606
22338
Related Questions
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Do oral NSAIDs and steroids have an effect on how you interpret synovial fluid leukocyte count?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
What do you include in your differential for patients with recurrent large volume, non-inflammatory joint effusions?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?